Design and engineering human forms of monoclonal antibodies

Drug Development Research

Volumn 61, Issue 3, 2004, Pages 121-136

  Penichet, Manuel L ^a   Morrison, Sherie L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibodies; Antibody fusion protein; Hybridoma; Immunotherapy; Phage library

Indexed keywords

ANTIBODY FUSION PROTEIN; BISPECIFIC ANTIBODY; CHIMERIC ANTIBODY; COMPLEMENTARY DNA; FC RECEPTOR; HUMAN MONOCLONAL ANTIBODY; HYBRID PROTEIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G3; MDX 210; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2B1; POLYMER; POLYMERIC ANTIBODY; RITUXIMAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; STEROID; TRANSFERRIN RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN BINDING; BREAST CANCER; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG DESIGN; GENETIC ENGINEERING; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; IMMUNOTHERAPY; INFECTION; INFLAMMATORY DISEASE; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PHAGE DISPLAY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW;

EID: 3843131713     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10347     Document Type: Review

References (107)

1. Abramowicz D, Crusiaux A, Goldman M. 1992. Anaphylactic shock after retreatment with OKT3 monoclonal antibody. N Engl J Med 327:736.
2. Anderson KC. 2001. Targeted therapy for multiple myeloma. Semin Hematol 38:286-294.
3. Anderson KC, Kyle RA, Dalton WS, Landowski T, Shain K, Jove R, Hazlehurst L, Berenson J. 2000. Multiple myeloma: new insights and therapeutic approaches. Hematology (Am Soc Hematol Educ Program) 147-165.
4. Atwell JL, Breheney KA, Lawrence LJ, McCoy AJ, Kortt AA, Hudson PJ. 1999. scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies. Protein Eng 12:597-604.
5. Bajorin DF, Chapman PB, Wong GY, Cody BV, Cordon-Cardo C, Dantes L, Templeton MA, Scheinberg D, Oettgen HF, Houghton AN. 1992. Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma. Melanoma Res 2:355-362.
6. Barbas CF, Bain JD, Hoekstra DM, Lerner RA. 1992. Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem. Proc Natl Acad Sci USA 89:4457-4461.
7. Biocca S, Pierandrei-Amaldi P, Campioni N, Cattaneo A. 1994. Intracellular immunization with cytosolic recombinant antibodies. Biotechnology (NY) 12:396-399.
8. Boulianne GL, Hozumi N, Shulman MJ. 1984. Production of functional chimaeric mouse/human antibody. Nature 312: 643-646.
9. Carter P. 2001. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1:118-129.
10. Challita-Eid PM, Penichet ML, Shin S-U, Mosammaparast N, Poles TM, Mahmood K, Slamon DL, Morrison SL, Rosenblatt JD. 1997. A B7.1-Ab fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway. J Immunol 160:3419-3426.
11. Chester KA, Bhatia J, Boxer G, Cooke SP, Flynn AA, Huhalov A, Mayer A, Pedley RB, Robson L, Sharma SK, Spencer DI, Begent RH. 2000a. Clinical applications of phage-derived sFvs and sFv fusion proteins. Dis Markers 16:53-62.
12. Chester KA, Mayer A, Bhatia J, Robson L, Spencer DI, Cooke SP, Flynn AA, Sharma SK, Boxer G, Pedley RB, Begent RH. 2000b. Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer. Cancer Chemother Pharmacol 46:S8-12.
13. Choy EH. 1998. Clinical pharmacology and therapeutic potential of monoclonal antibody treatment in rheumatoid arthritis. Drugs Aging 12:139-148.
14. Coloma MJ, Hastings A, Wims LA, Morrison SL. 1992. Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J Immunol Methods 152:89-104.
15. Coloma MJ, Morrison SL. 1997. Design and production of novel tetravalent bispecific antibodies [see comments]. Nature Biotechnol 15:159-163.
16. Dangl JL, Wensel TG, Morrison SL, Stryer L, Herzenberg LA, Oi VT. 1988. Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J 7:1989-1994.
17. Davis AC, Shulman MJ. 1989. IgM: molecular requirements for its assembly and function. Immunol Today 10:127-128.
18. Davis AC, Roux KH, Shulman MJ. 1988. On the structure of polymeric IgM. Eur J Immunol 18:1001-1008.
19. Davis AC, Roux KH, Pursey J, Shulman MJ. 1989. Intermolecular disulfide bonding in IgM: effects of replacing cysteine residues in the mu heavy chain. EMBO J 8:2519-2526.
20. Dubel S, Breitling F, Fuchs P, Zewe M, Gotter S, Welschof M, Moldenhauer G, Little M. 1994. Isolation of IgG antibody Fv-DNA from various mouse and rat hybridoma cell lines using the polymerase chain reaction with a simple set of primers. J Immunol Methods 175:89-95.
21. Dubel S, Breitling F, Kontermann R, Schmidt T, Skerra A, Little M. 1995. Bifunctional and multimeric complexes of streptavidin fused to single chain antibodies (scFv). J Immunol Methods 178:201-209.
22. Ernst M, Meier D, Sonneborn HH. 1999. From IgG monoclonals to IgM-like molecules. Human Antibodies 9:165-170.
23. Figini M, Marks JD, Winter G, Griffiths AD. 1994. In vitro assembly of repertoires of antibody chains on the surface of phage by renaturation. J Mol Biol 239:68-78.
24. George AJ, Titus JA, Jost CR, Kurucz I, Perez P, Andrew SM, Nicholls PJ, Huston JS, Segal DM. 1994. Redirection of T cell-mediated cytotoxicity by a recombinant single-chain Fv molecule. J Immunol 152:1802-1811.
25. Glassy MC. 1993. Production methods for generating human monoclonal antibodies. Human Antibod Hybrid 4:154-165.
26. Glennie MJ, McBride HM, Worth AT, Stevenson GT. 1987. Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments. J Immunol 139:2367-2375.
27. Glennie MJ, Brennand DM, Bryden F, McBride HM, Stirpe F, Worth AT, Stevenson GT. 1988. Bispecific F(ab' gamma)2 antibody for the delivery of saporin in the treatment of lymphoma. J Immunol 141:3662-3670.
28. Goldenberg MM. 1999. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 21:309-318.
29. Green LL. 1999. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J Immunol Methods 231:11-23.
30. Green NM. 1990. Avidin and streptavidin. Methods Enzymol 184:51-67.
31. Griffiths AD, Malmqvist M, Marks JD, Bye JM, Embleton MJ, McCafferty J, Baier M, Holliger KP, Gorick BD, Hughes-Jones NC, Hoogenboom HR, Winter G. 1993. Human anti-self antibodies with high specificity from phage display libraries. Embo J 12:725-734.
32. Hanes J, Jermutus L, Weber-Bornhauser S, Bosshard HR, Pluckthun A. 1998. Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries. Proc Natl Acad Sci USA 95:14130-14135.
33. Hayden MS, Gilliland LK, Ledbetter JA. 1997. Antibody engineering. Curr Opin Immunol 9:201-212.
34. He M, Taussig MJ. 1997. Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites. Nucleic Acids Res 25:5132-5134.
35. Higuchi K, Araki T, Matsuzaki O, Sato A, Kanno K, Kitaguchi N, Ito H. 1997. Cell display library for gene cloning of variable regions of human antibodies to hepatitis B surface antigen. J Immunol Methods 202:193-204.
36. Holliger P, Prospero T, Winter G. 1993. "Diabodies": small bivalent and bispecific antibody fragments, Proc Natl Acad Sci USA 90:6444-6448.
37. Hu S, Shively L, Raubitschek A, Sherman M, Williams LE, Wong JY, Shively JE, Wu AM. 1996. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 56:3055-3061.
38. Hudson PJ, Kortt AA. 1999. High avidity scFv multimers; diabodies and triabodies. J Immunol Methods 231:177-189.
39. Iliades P, Kortt AA, Hudson PJ. 1997. Triabodies: single chain Fv fragments without a linker form trivalent trimers. FEBS Lett 409:437-441.
40. Jaffers GJ, Fuller TC, Cosimi AB, Russell PS, Winn HJ, Colvin RB. 1986. Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression. Transplantation 41:572-578.
41. James K, Bell GT. 1987. Human monoclonal antibody production. Current status and future prospects. Journal of Immunological Methods 100:5-40.
42. James ND, Atherton PJ, Jones J, Howie AJ, Tchekmedyian S, Curnow RT. 2001. A phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HER2+ advanced prostate cancer. Br J Cancer 85:152-156.
43. Janeway CA, Travers P, Walport M, Shlomchik M. 2001. The generation of lymphocyte antigen receptors. In: Immunobiology: the immune system in health and disease, 5th ed. New York: Garland Publishing. p 123-154.
44. Jespers LS, Roberts A, Mahler SM, Winter G, Hoogenboom HR. 1994. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Biotechnology (NY) 12:899-903.
45. Kawa K. 2000. Epstein-Barr virus-associated diseases in humans. Int J Hematol 71:108-17.
46. Kohler G, Milstein C. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497.
47. Kontsekova E, Kolcunova A, Kontsek P. 1992. Quadroma-secreted bi(interferon alpha 2-peroxidase) specific antibody suitable for one-step immunoassay. Hybridoma 11:461-468.
48. Kortt AA, Lah M, Oddie GW, Gruen CL, Burns JE, Pearce LA, Atwell JL, McCoy AJ, Howlett GJ, Metzger DW, Webster RG, Hudson PJ. 1997. Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer. Protein Eng 10:423-433.
49. Kostelny SA, Cole MS, Tso JY. 1992. Formation of a bispecific antibody by the use of leucine zippers. J Immunol 148:1547-1553.
50. Kriangkum J, Xu B, Nagata LP, Fulton RE, Suresh MR. 2001. Bispecific and bifunctional single chain recombinant antibodies. Biomol Eng 18:31-40.
51. Kuroiwa Y, Kasinathan P, Choi YJ, Naeem R, Tomizuka K, Sullivan EJ, Knott JG, Duteau A, Goldsby RA, Osborne BA, Ishida I, Robl JM. 2002. Cloned transchromosomic calves producing human immunoglobulin. Nat Biotechnol 20:889-894.
52. Kuus-Reichel K, Grauer LS, Karavodin LM, Knott C, Krusemeier M, Kay NE. 1994. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin Diagn Lab Immunol 1:365-372.
53. Larrick JW, Danielsson L, Brenner CA, Abrahamson M, Fry KE, Borrebaeck CA. 1989. Rapid cloning of rearranged immunoglobulin genes from human hybridoma cells using mixed primers and the polymerase chain reaction. Biochem Biophys Res Commun 160:1250-1256.
54. LeBoeuf RD, Galin FS, Hollinger SK, Peiper SC, Blalock JE. 1989. Cloning and sequencing of immunoglobulin variable-region genes using degenerate oligodeoxyribonucleotides and polymerase chain reaction. Gene 82:371-377.
55. Leget GA, Czuczman MS. 1998. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 10:548-551.
56. Lewis LD, Cole BF, Wallace PK, Fisher JL, Waugh M, Guyre PM, Fanger MW, Curnow RT, Kaufman PA, Ernstoff MS. 2001. Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu. J Immunol Methods 248:149-165.
57. Liu AY, Robinson RR, Hellstrom KE, Murray ED Jr, Chang CP, Hellstrom I. 1987. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci USA 84:3439-3443.
58. Liu SJ, Sher YP, Ting CC, Liao KW, Yu CP, Tao MH. 1998. Treatment of B-cell lymphoma with chimeric IgG and single-chain Fv antibody-interleukin-2 fusion proteins. Blood 92: 2103-2112.
59. Lloyd F Jr, Goldrosen M. 1991. The production of a bispecific anti-CEA, anti-hapten (4-amino- phthalate) hybrid-hybridoma. J Natl Med Assoc 83:901-904.
60. Lode HN, Xiang R, Becker JC, Gillies SD, Reisfeld RA. 1998. Immunocytokines: a promising approach to cancer immunotherapy. Pharmacol Therapeut 80:277-292.
61. Lynch DH, Yang XD. 2002. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol 29:47-50.
62. Mallender WD, Voss EW, Jr. 1994. Construction, expression, and activity of a bivalent bispecific single-chain antibody. J Biol Chem 269:199-206.
63. Marasco WA. 1997. Intrabodies: turning the humoral immune system outside in for intracellular immunization. Gene Ther 4:11-15.
64. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. 1991. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 222:581-597.
65. McGrath JP, Cao X, Schutz A, Lynch P, Ebendal T, Coloma MJ, Morrison SL, Putney SD. 1997. Bifunctional fusion between nerve growth factor and a transferrin receptor antibody. J Neurosci Res 47:123-133.
66. Mendez MJ, Green LL, Corvalan JR, Jia XC, Maynard-Currie CE, Yang XD, Gallo ML, Louie DM, Lee DV, Erickson KL, Luna J, Roy CM, Abderrahim H, Kirschenbaum F, Noguchi M, Smith DH, Fukushima A, Hales JF, Klapholz S, Finer MH, Davis CG, Zsebo KM, Jakobovits A. 1997. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice [published erratum appears in Nat Genet 1997 Aug;16(4):410]. Nat Genet 15:146-156.
67. Mendez MJ, Green LL, Corvalan JR, Jia XC, Maynard-Currie CE, Yang XD, Gallo ML, Louie DM, Lee DV, Erickson KL, Luna J, Roy CM, Abderrahim H, Kirschenbaum F, Noguchi M, Smith DH, Fukushima A, Hales JF, Klapholz S, Finer MH, Davis CG, Zsebo KM, Jakobovits A. 1997. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice [published erratum appears in Nat Genet 1997 Aug;16(4):410]. Nat Genet 15:146-156.
68. Milstein C, Cuello AC. 1983. Hybrid hybridomas and their use in immunohistochemistry. Nature 305:537-540.
69. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM. 1997. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein [see comments]. N Engl J Med 337:141-147.
70. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange ML, McDonnell ND, Weinblatt ME. 1999. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130:478-486.
71. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. 1984. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 81:6851-6855.
72. Ng PP, Dela Cruz JS, Sorour DN, Stinebaugh JM, Shin SU, Shin DS, Morrison SL, Penichet ML. 2002. An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells. Proc Natl Acad Sci USA 99:10706-10711.
73. Orlandi R, Gussow DH, Jones PT, Winter G. 1989. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc Natl Acad Sci USA 86:3833-3837.
74. Pack P, Pluckthun A. 1992. Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli. Biochemistry 31:1579-1584.
75. Parmley SF, Smith GP. 1988. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene 73:305-318.
76. Peng LS, Penichet ML, Morrison SL. 1999. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity. J Immunol 163:250-258.
77. Penichet ML, Harvill ET, Morrison SL. 1998. An IgG3-IL-2 fusion protein recognizing a murine B cell lymphoma exhibits effective tumor imaging and antitumor activity. J Interferon Cytokine Res 18:597-607.
78. Penichet ML, Shin SU, Morrison SL. 1999. Fab fusion proteins: Immunoligands. In: Antibody Fusion Proteins. Chamow SM, Ashkenazi A, editors. New York: Wiley-Liss, Inc. p 15-52.
79. Penichet ML, Dela Cruz JS, Shin SU, Morrison SL. 2001. A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors. Hum Antibod 10:43-49.
80. Pluckthun A, Pack P. 1997. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 3:83-105.
81. Powers DB, Marks JD. 1999. Monovalent phage display of Fab and scFv fusions. In: Chamow SM, Ashkenazi A, editors. Antibody fusion proteins. New York: Wiley-Liss, Inc. p 151-188.
82. Rader C, Barbas CF. 1997. Phage display of combinatorial antibody libraries. Curr Opin Biotechnol 8:503-508.
83. Raso V, Griffin T. 1981. Hybrid antibodies with dual specificity for the delivery of ricin to immunoglobulin-bearing target cells. Cancer Res 41:2073-2078.
84. Russell SJ, Hawkins RE, Winter G. 1993. Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res 21:1081-1085.
85. Schiller GJ. 1993. Multiple myeloma, heavy chain diseases, and Waldenstrom's macroglobulinemia. In: Bick RL, editor. Hematology: clinical and laboratory practice, Vol. 1. Saint Louis, MO: Mosby-Year Book Inc. p 705-727.
86. Shin SU, Wu D, Ramanathan R, Pardridge WM, Morrison SL. 1997. Functional and pharmacokinetic properties of antibody-avidin fusion proteins. J Immunol 158:4797-4804.
87. Shusta EV, Kieke MC, Parke E, Kranz DM, Wittrup KD. 1999. Yeast polypeptide fusion surface display levels predict thermal stability and soluble secretion efficiency. J Mol Biol 292:949-956.
88. Smith GP. 1985. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228:1315-1317.
89. Smith RI, Coloma MJ, Morrison SL. 1995. Addition of a mu-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4. J Immunol 154:2226-2236.
90. Smith RI, Morrison SL. 1994. Recombinant polymeric IgG: an approach to engineering more potent antibodies. Biotechnology (NY) 12:683-688.
91. Somia NV, Zoppe M, Verma IM. 1995. Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery. Proc Natl Acad Sci USA 92:7570-7574.
92. Tada H, Kurokawa T, Seita T, Watanabe T, Iwasa S. 1994. Expression and characterization of a chimeric bispecific antibody against fibrin and against urokinase-type plasminogen activator. J Biotechnol 33:157-174.
93. Tomizuka K, Shinohara T, Yoshida H, Uejima H, Ohguma A, Tanaka S, Sato K, Oshimura M, Ishida I. 2000. Double transchromosomic mice: maintenance of two individual human chromosome fragments containing Ig heavy and kappa loci and expression of fully human antibodies. Proc Natl Acad Sci USA 97:722-727.
94. Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Deo Y, Graziano R, Fisher JL, Meyer L, Mrozek-Orlowski M, et al. 1995. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J Clin Oncol 13:2281-2292.
95. van Dijk MA, van de Winkel JG. 2001. Human antibodies as next generation therapeutics. Curr Opin Chem Biol 5:368-374.
96. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, McCafferty J, Hodits RA, Wilton J, Johnson KS. 1996. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 14:309-314.
97. Verhoeyen M, Milstein C, Winter G. 1988. Reshaping human antibodies: grafting an antilysozyme activity. Science 239:1534-1536.
98. Verma R, Boleti E, George AJ. 1998. Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems. J Immunol Methods 216:165-181.
99. Weiner HL. 1994. Oral tolerance. Proc Natl Acad Sci USA 91:10762-10765.
100. Weiner LM, Clark JI, Ring DB, Alpaugh RK. 1995. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. J Hematother 4:453-456.
101. Weinstein JN, Eger RR, Covell DG, Black CD, Mulshine J, Carrasquillo JA, Larson SM, Keenan AM. 1987. The pharmacology of monoclonal antibodies. Ann NY Acad Sci 507:199-210.
102. Winter G, Milstein C. 1991. Man-made antibodies. Nature 349:293-299.
103. Wright A, Shin SU, Morrison SL. 1992. Genetically engineered antibodies: progress and prospects. Crit Rev Immunol 12:125-168.
104. Wu AM, Yazaki PJ. 2000. Designer genes: recombinant antibody fragments for biological imaging. Q J Nucl Med 44:268-283.
105. Yoo EM, Chintalacharuvu KR, Penichet ML, Morrison SL. 2002. Myeloma expression systems. J Immunol Methods 261:1-20.
106. Zhu D, Kepley CL, Zhang M, Zhang K, Saxon A. 2002. A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation. Nat Med 8:518-521.
107. Zuckier LS, Rodriguez LD, Scharff MD. 1989. Immunologic and pharmacologic concepts of monoclonal antibodies. Semin Nucl Med 19:166-186.